BiotechTube
AlphaMol Science

AlphaMol Science

Basel, Switzerland· Est.
alphamol.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

AlphaMol Science is a private, pre-clinical stage biotech targeting protein-protein interactions with small molecules, a historically undruggable target class. Leveraging its location in the Basel life sciences hub, the company aims to create novel therapies for oncology, with potential expansion into other therapeutic areas. As a platform-focused company, its success hinges on validating its proprietary drug discovery technology and advancing its lead programs into clinical development to attract partnership and investment.

Oncology

Technology Platform

Proprietary drug discovery platform for identifying and optimizing small molecules that target protein-protein interactions (PPIs), integrating computational chemistry, structural biology, and medicinal chemistry.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The successful drugging of protein-protein interactions represents a vast, untapped frontier in therapeutics, particularly in oncology.
A validated platform could generate multiple high-value drug candidates and attract significant partnership interest from large pharmaceutical companies.
Basel's ecosystem provides excellent access to talent, capital, and potential collaborators.

Risk Factors

The core scientific challenge of developing potent, selective, and drug-like small molecules against PPIs is extremely high, with a significant risk of technical failure.
The company faces intense competition from other biotechs and pharmas exploring similar approaches.
As a pre-revenue private company, it is highly dependent on external financing, which can be volatile.

Competitive Landscape

AlphaMol operates in a highly competitive space alongside other biotechs specializing in PPIs (e.g., Ideaya Biosciences in the past) and a growing number of companies focused on targeted protein degradation (e.g., Arvinas, C4 Therapeutics) which offers an alternative approach to modulating protein function. Large pharmaceutical companies also have internal efforts in this area, making the race for validated targets intense.

More companies in Switzerland →